ROR1 targeting agents, such as siRNA, monoclonal antibodies (mAbs), chimeric antigen receptor-modified T cells (CAR-T), and small molecule inhibitors (SMI), induced significant tumor cell death in hematological malignancies and cancers of epithelial origin [31,36,37,41,42,43,44,45]. This evidence concerns the gene ROR1 and hematologic disorder.